Sissetulev kiriAvalik
Lasteravimite formulari asjus
Ravimiamet · 23. mai 2024
- Viit
- REP-1/1893-1
- Registreeritud
- 23. mai 2024
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2024
- Vastutaja
- Signe Leito (RA, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: teisipäev, 14. mai 2024 18:42
Adressaat: Signe Leito
Teema: Proposed addition to the PaedF WP: Prednisolone oral liquid: EDQM-2024-02012-mail
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2024-02012-mail
****************************************************************************
For the attention of NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of Prednisolone oral liquid to the work programme of the
European Paediatric Formulary.
In order to have access to the survey, please copy and paste this link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=918965&lang=en
Deadline for replies: 4 June 2024
With kind regards,
On behalf of Jane Francomb
Bénédicte Bunner
1
Administrative Support Assistant
European Pharmacopoeia Department (EPD)
European Directorate for the Quality of Medicines & HealthCare (EDQM)
Council of Europe - Conseil de l'Europe
To reach us, we invite you to contact us electronically. You can also contact us via HelpDesk
https://www.edqm.eu / https://www.edqm.eu/store
Stay connected with the EDQM
Confidentiality Notice:
This e-mail and any attached files may contain confidential information that is intended only for the addressee(s).
If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or reliance upon the contents of this e-mail (including any attached files) is strictly prohibited. Anyone who receives this message in error should
notify the sender immediately by using the reply function and then permanently delete this e-mail (including any attached files).
Thank you.
****************************************************************************
Please make sure to include in any reply our mail reference: EDQM-2024-02012-mail
2